What is the appropriate aztreonam dosage for treating pneumonia in adults, including adjustments for renal impairment?

Aztreonam Dosing for Pneumonia

For hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP), administer aztreonam 2 g IV every 8 hours as part of combination therapy targeting gram-negative pathogens, particularly Pseudomonas aeruginosa. 111

Standard Dosing for Pneumonia

The 2016 IDSA/ATS guidelines for HAP/VAP explicitly recommend aztreonam 2 g IV every 8 hours when antipseudomonal coverage is needed 111. This dose is specifically indicated for:

• Severe systemic or life-threatening infections including pneumonia
• Pseudomonas aeruginosa infections where the 2 g dose every 6-8 hours is recommended at least initially 2
• Patients at high risk of mortality or those who received IV antibiotics in the prior 90 days 1

Critical point: Aztreonam should NOT be used as monotherapy for pneumonia. It must be combined with agents covering gram-positive organisms (particularly MRSA if risk factors present) since aztreonam only covers aerobic gram-negative bacteria 12.

Renal Dose Adjustments

Dosing must be modified based on creatinine clearance (CrCl) 22:

Initial Loading Dose: Give full dose (1-2 g) regardless of renal function 2

Maintenance Dosing:

• CrCl 10-30 mL/min: Reduce maintenance dose to 50% of usual dose (1 g instead of 2 g) at standard intervals 2
• CrCl <10 mL/min (including hemodialysis): Give 25% of usual initial dose (500 mg) at standard intervals, plus one-eighth of initial dose after each hemodialysis session 2
• CrCl >30 mL/min: No adjustment needed 2

Recent pharmacokinetic modeling confirms these adjustments maintain adequate target attainment (>90% probability) even in moderate-to-severe renal impairment 3.

Administration Details

• Route: IV administration is mandatory for pneumonia (intramuscular route inadequate for severe infections) 2
• Infusion time: Standard 30-minute infusion 22. Extended infusions (2-3 hours) may be considered for optimization, particularly in critically ill patients 11
• Duration: Continue for at least 48 hours after clinical improvement or bacterial eradication; persistent infections may require several weeks 2

Combination Therapy Requirements

For empiric HAP/VAP treatment, aztreonam must be paired with 1:

1. MRSA coverage (vancomycin 15 mg/kg IV q8-12h OR linezolid 600 mg IV q12h) if risk factors present
2. Alternative gram-positive coverage (piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem) if MRSA coverage not needed

Important caveat: Aztreonam can be used as an adjunctive agent with another β-lactam despite both being β-lactams, because it targets different bacterial cell wall components 11. This is particularly relevant for MBL-producing organisms when combined with ceftazidime-avibactam 4.

Pharmacokinetic Considerations

• Peak serum levels after 2 g IV dose: 204 mcg/mL immediately post-infusion 2
• Serum half-life: 1.7 hours in normal renal function, prolonged with renal impairment 2
• Achieves therapeutic concentrations in bronchial secretions (mean 5 mcg/mL at 4 hours post-dose) and lung tissue (mean 22 mcg/mL) 22

Elderly patients: Require particular attention to renal function assessment; serum creatinine alone may be unreliable—calculate CrCl using Cockcroft-Gault equation and adjust accordingly 2.

The 2 g every 8 hours regimen maintains serum levels exceeding MIC90 for most Enterobacteriaceae for 8 hours and for Pseudomonas aeruginosa for 4-6 hours 2, supporting the q8h dosing interval for pneumonia.